Literature DB >> 12823125

Various factors (allergen nature, mouse strain, CpG/recombinant protein expressed) influence the immune response elicited by genetic immunization.

J M Chatel1, L Song, B Bhogal, F M Orson.   

Abstract

BACKGROUND: Genetic immunization is a very promising therapeutic approach for allergy treatment. In the present study we investigate the influence of the nature of the allergen, the mouse strain, and the relative amount of CpG to expressed recombinant protein on immune responses using two major peanut allergens, Ara h 1 and Ara h 4.
METHODS: The cDNA of Ara h 1 and of an isoform of Ara h 4 were cloned and inserted in pcDNA3. Antigen specific IgG1, IgG2a and IgE were followed after genetic immunization with 100 microg of these clones in mouse strain SKH-Hr1 or BALB/c and with 1 microg of the clones+99 blank plasmid in SKH-Hr1.
RESULTS: Genetic immunization in SKH-Hr1 with Ara h 1 elicited a classical Th1 type response, but Ara h 4 elicited a mixed Th1/Th2 response with high IgG1 and even IgE in some mice. In BALB/c both plasmids produced a high IgG1 level. Decreasing the amount of plasmid injected did not change the immune response profile. However, increasing the amount of CpG administered relative to the recombinant Ara h 4 protein expressed reversed the Th1/Th2 response pattern in SKH-Hr1 mice.
CONCLUSIONS: Immune responses after genetic immunization are strongly influenced by the nature of the allergen, the mouse strain, and the ratio of CpG to recombinant protein expressed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823125     DOI: 10.1034/j.1398-9995.2003.00182.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

1.  Similar response in male and female B10.RIII mice in a murine model of allergic airway inflammation.

Authors:  Victor Matheu; Ysamar Barrios; Maria-Rosa Arnau; Vaidrius Navikas; Shohreh Issazadeh-Navikas
Journal:  Inflamm Res       Date:  2009-09-25       Impact factor: 4.575

Review 2.  Developing therapies for peanut allergy.

Authors:  Merima Bublin; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2014-12-20       Impact factor: 2.749

3.  Immune response elicited by DNA vaccination using Lactococcus lactis is modified by the production of surface exposed pathogenic protein.

Authors:  Daniela Pontes; Marcela Azevedo; Silvia Innocentin; Sébastien Blugeon; François Lefévre; Vasco Azevedo; Anderson Miyoshi; Pascal Courtin; Marie-Pierre Chapot-Chartier; Philippe Langella; Jean-Marc Chatel
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.